GHK-Cu and Smoke-Related Muscle Dysfunction: Study Summary
This multi-part study combined a small human comparison with cell and mouse experiments investigating GHK-Cu in cigarette-smoke-related skeletal-muscle dysfunction.
Study design
Plasma GHK was measured in nine people with COPD and 11 controls. Researchers then used C2C12 myotubes and smoke-exposed mice to assess muscle markers, oxidative stress, mitochondrial measures, muscle mass and grip strength.
What the researchers reported
Lower plasma GHK was observed in the small COPD group. In the experimental models, GHK-Cu was associated with improved muscle-related measurements, and mechanistic experiments implicated SIRT1-dependent signalling.
What this result does not establish
The human component was observational and very small; experimental treatment findings came from cells and mice. Together they do not demonstrate that GHK-Cu treats muscle dysfunction in people with COPD.
This article summarizes one published study about GHK-Cu. It does not establish clinical efficacy, general safety, regulatory approval or suitability for human use. Findings should be interpreted within the model, methods and limitations of the original paper.
Related research material
Review the corresponding catalogue listing, labelled amount and available documentation. The study may use a different formulation or experimental preparation; it does not verify our product, its batch or suitability for human use.
Our Approach
Evidence before assumption.
TAM Global Research focuses on transparent documentation, careful scientific interpretation and clear distinction between what available evidence supports and what requires further verification.
Explore our quality standards